Literature DB >> 16319950

Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung.

U Griesenbach1, R J Boyton, L Somerton, S E Garcia, S Ferrari, T Owaki, Z Ya-Fen, D M Geddes, M Hasegawa, D M Altmann, E W F W Alton.   

Abstract

Sendai virus (SeV) is able to transfect airway epithelial cells efficiently in vivo. However, as with other viral vectors, repeated administration leads to reduced gene expression. We have investigated the impact of inducing immunological tolerance to immunodominant T-cell epitopes on gene expression following repeated administration. Immunodominant CD4 and CD8 T-cell peptide epitopes of SeV were administered to C57BL/6 mice intranasally 10 days before the first virus administration with transmission-incompetent F-protein-deleted DeltaF/SeV-GFP. At 21 days after the first virus administration, mice were again transfected with DeltaF/SeV. To avoid interference of anti-GFP antibodies, the second transfection was carried out with DeltaF/SeV-lacZ. At 2 days after the final transfection lung beta-galactosidase expression, T-cell proliferation and antibody responses were measured. A state of 'split tolerance' was achieved with reduced T-cell proliferation, but no impact on antiviral antibody production. There was no enhancement of expression on repeat administration; instead, T-cell tolerance was, paradoxically, associated with a more profound extinction of viral expression. Multiple immune mechanisms operate to eradicate viruses from the lung, and these findings indicate that impeding the adaptive T-cell response to the immunodominant viral epitope is not sufficient to prevent the process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16319950     DOI: 10.1038/sj.gt.3302677

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression.

Authors:  Olga Malykhina; Mark A Yednak; Peter L Collins; Paul D Olivo; Mark E Peeples
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

2.  Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli.

Authors:  M D B Larsen; U Griesenbach; S Goussard; D C Gruenert; D M Geddes; R K Scheule; S H Cheng; P Courvalin; C Grillot-Courvalin; E W F W Alton
Journal:  Gene Ther       Date:  2008-01-24       Impact factor: 5.250

Review 3.  Cystic Fibrosis Gene Therapy in the UK and Elsewhere.

Authors:  Uta Griesenbach; Kamila M Pytel; Eric W F W Alton
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 5.695

4.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Authors:  Eric W F W Alton; Jeffery M Beekman; A Christopher Boyd; June Brand; Marianne S Carlon; Mary M Connolly; Mario Chan; Sinead Conlon; Heather E Davidson; Jane C Davies; Lee A Davies; Johanna F Dekkers; Ann Doherty; Sabrina Gea-Sorli; Deborah R Gill; Uta Griesenbach; Mamoru Hasegawa; Tracy E Higgins; Takashi Hironaka; Laura Hyndman; Gerry McLachlan; Makoto Inoue; Stephen C Hyde; J Alastair Innes; Toby M Maher; Caroline Moran; Cuixiang Meng; Michael C Paul-Smith; Ian A Pringle; Kamila M Pytel; Andrea Rodriguez-Martinez; Alexander C Schmidt; Barbara J Stevenson; Stephanie G Sumner-Jones; Richard Toshner; Shu Tsugumine; Marguerite W Wasowicz; Jie Zhu
Journal:  Thorax       Date:  2016-11-16       Impact factor: 9.139

5.  Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

Authors:  Uta Griesenbach; Makoto Inoue; Cuixiang Meng; Raymond Farley; Mario Chan; Nikki K Newman; Andrea Brum; Jun You; Angela Kerton; Amelia Shoemark; A Christopher Boyd; Jane C Davies; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes; David J Porteous; Mamoru Hasegawa; Eric W F W Alton
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.